One of the only companies worldwide offering an integrated solution across the full HPV continuum: from how the virus drives cancer, to detecting infection and transformation, to supporting the next generation of HPV drugs and vaccines.
Independent research and clinical pathology groups have published more than 110 papers with Enzo HPV reagents. This is what the results look like.
years of HPV innovation
peer-reviewed publications including Nature
countries where investigators have published with Enzo HPV reagents
HPV dedicated products across DNA ISH, RNA ISH, IHC and IF platforms
specimen types validated including cervix, head and neck, anogenital, lung, adipose, cell lines
automated leading staining platforms validated, plus manual workflows
A product × platform × specimen validation matrix with full citations is available to customers on request.
Nearly 80% of sexually active people will acquire at least one HPV infection. Most clear on their own. Persistent infection with a high-risk genotype drives cervical, oropharyngeal, anal, vulvar, vaginal and penile cancers, roughly 5% of all cancers worldwide.
HPV-attributable cancer cases a year (IARC, de Martel 2020)
of those cancers are cervical, the largest single HPV disease burden
new cervical cancer cases a year (GLOBOCAN 2022)
cervical cancer deaths a year (GLOBOCAN 2022)
From the first non-radioactive HPV probe in 1986 to the 15-genotype AMPIVIEW® HR-15 panel in 2025 — Enzo Life Sciences has been pioneering HPV detection since 1986.
“Results with the Enzo probe were so good that we did not continue trying to optimize with a different probe.”
In most people the viral genome stays episomal and the immune system clears it. In some, it integrates into host DNA, disrupts E2 and lets the E6 and E7 oncoproteins run unchecked.
E7 inactivates pRb, releases E2F and forces S-phase entry. The cell responds by overexpressing p16INK4a, the IHC surrogate marker of E7 activity.
E6 degrades p53 through E6-AP, switching off apoptosis and the DNA-damage response. It also drives c-myc and hTERT, so cells bypass senescence.
Detect HPV at the DNA level (viral presence and genotype), at the RNA level (transcriptionally active E6/E7) or at the protein level (p16 and Ki-67 markers). Every ISH format comes in more than one hapten, so the probe chemistry matches your detection system, automated platform or multiplex workflow.
| Genotype panel | DNA · BiotinPATHO-GENE® | DNA · DigoxigeninDIGX® | RNA · DigoxigeninAMPIVIEW® LoopRNA™ | RNA · DNPAMPIVIEW® LoopRNA™ |
|---|---|---|---|---|
| HPV 6/11Low-risk · condyloma | ENZ-32885 | ENZ-GEN112 | ENZ-GEN145 | Custom available |
| HPV 16/18~70% of cervical cancer | ENZ-32886 | ENZ-GEN113 | ENZ-GEN146 | Custom available |
| HPV 31/33/51High-risk · IARC Group 1 | ENZ-32887 | Custom available | ENZ-GEN147 | Custom available |
| HPV 16/18/31/33/515-type high-risk panel | ENZ-32882 | ENZ-GEN114 | ENZ-GEN148 | Custom available |
| HR-15 panelIARC Group 1 + 2A + 2B | — | ENZ-GEN360 NEW | — | ENZ-GEN320 NEW |
| HPV 6/11/16/18/31/33/51Full screening panel | ENZ-32884 | — | Custom available | Custom available |
| Ki-67 (AS)Proliferation marker | — | — | ENZ-GEN271 | ENZ-GEN304 |
Custom probes: 1–2 week delivery through the Enzo custom probe design service.
HPV surrogate biomarker for cervical, head and neck, anogenital and adenosquamous neoplasia. Also used as a senescence marker.
Published on Leica BOND, BOND-RX and BOND-MAX, Dako EnVision (manual IHC) and confocal immunofluorescence.
Proliferation marker: companion IHC for HPV lesion grading and for drug and vaccine efficacy readouts.
Pair with POLYVIEW® PLUS HRP-DAB detection (ENZ-KIT159/160) and HIGHDEF® chromogens.
Researchers moving from screening to functional characterization don’t switch vendors, re-validate protocols or compromise on sensitivity.
AMPIVIEW® HPV HR-15 (AS) DNP RNA Probes Set · ENZ-GEN320
It covers all 12 Group 1 types, the Group 2A type (68) and Group 2B types 66 and 82, in line with the IARC Monographs (Vol. 90 and 100B) and the WHO 2017 high-risk list.
Cervical intraepithelial neoplasia is graded by how much of the epithelium dysplastic cells occupy, read together with the molecular signature of HPV activity. The lesion advances on its own, stage by stage. Pick a stage to pause on it, or press Auto-play to resume.
CIN grading: Richart RM, Obstet Gynecol 1990;75:131–3 · WHO Classification of Tumours, Female Genital Tumours, 5th ed. (2020) · LAST Project, Darragh et al., Arch Pathol Lab Med 2012;136:1266–97.
Prevention now reaches beyond prophylactic vaccination: therapeutic vaccines, HPV-targeted immunotherapies, antivirals and gene-silencing agents. Enzo supplies reagents from target identification and mechanism studies to vaccine development and biologics manufacturing.
Understand how HPV drives disease, find the right target and confirm that your candidate hits it.
Characterize HPV antigens and measure the immune response to vaccines and immunotherapies.
Control the yield, purity and stability of HPV vaccines and HPV-targeted antibodies.
From the first non-radioactive probe in 1986 to the 15-genotype AMPIVIEW® HR-15 panel in 2025.
Sources. IARC Monographs Vol. 90 (2007) and Vol. 100B (2012) · WHO HPV Laboratory Manual, 2nd ed. (2019) · GLOBOCAN 2022 (WHO/IARC) · Enzo brochure MB27-HPV-REV10072022 · Enzo HPV publication library.
For research use only. Not for use in diagnostic procedures. All product names, logos and brands are the property of their respective owners. © 2026 Enzo Life Sciences.
Lab Essentials
AMPIVIEW® RNA probes
Enabling Your Projects 
GMP Services
Bulk Solutions
Research Travel Grant
Have You Published Using an Enzo Product?